To include your compound in the COVID-19 Resource Center, submit it here.

NexImmune’s next act

How differing opinions on pipeline strategy led to NexImmune buyout

Management’s and investors’ different views about what product to develop first was the catalyst for the sale of immuno-oncology play NexImmune Inc. to a new syndicate led by Sol Barer, chairman of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA;

Read the full 376 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE